Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (4)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
Postmenopausal women with the breast-cancer indications covered by the selected U.S. label; oral anastrozole tablets.
Renal measure
Qualitative renal guidance; no CrCl threshold for dose reduction.
Source revision
Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved
2026-09-05 (not the revision date)
Labeled basic dosing
Give 1 mg orally once daily, with or without food. Duration is indication-specific and should follow the oncology treatment plan.
Renal information and dialysis
The selected U.S. label requires no dose change for renal impairment because renal dysfunction does not materially affect total-body clearance.
Selected warnings and limits
Review bone-density loss and cholesterol effects. Estrogen-containing therapy can oppose the treatment effect; concurrent tamoxifen is not recommended.
Source revision: Label revision date not separately recorded; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Renal Drug Handbook, fifth edition - Anastrozole tablets
Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.
Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods. Retrieved: 2026-09-05
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
Arimidex - product and source limitations
Apply the usual indication-specific regimen. The renal subsection does not provide a dialysis timing instruction.
How to use this: Apply only to the stated formulation, indication and renal population.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
Anastrozole tablets - selected U.S. labeling
Postmenopausal women with the breast-cancer indications covered by the selected U.S. label; oral anastrozole tablets.
Method: Qualitative renal guidance; no CrCl threshold for dose reduction.
Renal Drug Handbook, fifth edition - Anastrozole tablets
Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.
Method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
U.S. product labeling / DailyMed · Postmenopausal women with the breast-cancer indications covered by the selected U.S. label; oral anastrozole tablets.
Renal method: Qualitative renal guidance; no CrCl threshold for dose reduction. Source date: Label revision date not separately recorded; retrieval date is not the revision date. Retrieved: 2026-09-05
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Labeled basic dosing
Give 1 mg orally once daily, with or without food. Duration is indication-specific and should follow the oncology treatment plan.
Review bone-density loss and cholesterol effects. Estrogen-containing therapy can oppose the treatment effect; concurrent tamoxifen is not recommended.
Renal method: Clinical renal category or population named in the cited section Source date: DailyMed SPL version 12, effective 2026-03-02; posted Mar 05, 2026 Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
No renal dose modification is necessary. Apply the usual indication-specific regimen. The renal subsection does not provide a dialysis timing instruction.
RDM73-arimidex-official-1 · Source locator: Renal guidance: 2.1 and 8.6
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
UK Renal Pharmacy Group / CRC Press · Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.
Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods. Source date: Fifth edition, 2019 Retrieved: 2026-09-05
Historical source, separately displayed. Renal tables were read with page-image inspection.
Historical renal and dialysis observations
The book retains standard dosing in all three renal bands and its listed dialysis modalities. Its commentary explicitly contrasts U.S. no-reduction advice with an older UK recommendation to avoid use below 20 mL/min.
RDM31-anastrozole-book · Source locator: Dose in renal impairment; renal replacement therapies; Other information
Source-specific limits
That UK restriction is a historical statement in the 2019 book, not a claim about current UK labeling. Do not import it into the U.S. dose rule.
Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page(s) 71; PDF page(s) 90
Renal-function method
Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
